La maladie de Parkinson en France (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Olivier Rascol76
Antiparkinsonien263
Olivier Rascol Sauf Antiparkinsonien" 65
Antiparkinsonien Sauf Olivier Rascol" 252
Olivier Rascol Et Antiparkinsonien 11
Olivier Rascol Ou Antiparkinsonien 328
Corpus2807
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 11.
Ident.Authors (with country if any)Title
000020 Santiago Perez-Lloret [France] ; María Ver Nica Rey [France] ; James Crispo [Canada] ; Daniel Krewski [Canada] ; Marise Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France]Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
000083 Santiago Perez-Lloret [France, Argentine] ; Maria Veronica Rey [France] ; Pietro Lucca Ratti [France] ; Olivier Rascol [France]Rotigotine transdermal patch for the treatment of Parkinson's Disease
000655 C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Robert Hauser [États-Unis] ; Paul D. Feigin [Israël] ; Joseph Jankovic [États-Unis] ; Anthony Lang [Canada] ; William Langston [États-Unis] ; Eldad Melamed [Israël] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne]A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
000937 Jean-Louis Montastruc [France] ; Agnès Sommet [France] ; Pascale Olivier [France] ; Haieh Bagheri [France] ; Mireille Gony [France] ; Maryse Lapeyre-Mestre [France] ; Christine Brefel-Courbon [France] ; Joachim Ferreira [Portugal] ; Laurent Schmitt [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France]Médicaments, maladie de Parkinson et syndromes parkinsoniens : actualités de pharmacovigilance
000D70 Olivier Rascol [France] ; Pierre Payoux [France, Portugal] ; Fabienne Ory [France] ; Joaquim J. Ferreira [France] ; Christine Brefel-Courbon [France] ; Jean-Louis Montastruc [France]Limitations of current Parkinson's disease therapy. Discussion
000D80 Marc Ziegler [France] ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France]Efficacy of Piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study
001030 Jean-Louis Montastruc [France] ; Christine Brefel-Courbon [France] ; Jean-Michel Senard [France] ; Haleh Bagheri [France] ; Joaquim Ferreira [France] ; Olivier Rascol [France] ; Maryse Lapeyre-Mestre [France]Sleep attacks and antiparkinsonian drugs : A pilot prospective pharmacoepidemiologic study
001048 Jean-Louis Montastruc [France] ; Karine Desboeuf [France] ; Maryse Lapeyre-Mestre [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Christine Brefel-Courbon [France]Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease
001077 Olivier Rascol [France] ; Nelly Fabre [France]Dyskinesia: L-dopa-induced and tardive dyskinesia
001231 C. Warren Olanow [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France]Continuous dopamine-receptor stimulation in early Parkinson's disease
001246 Jean-Louis Montastruc [France] ; Cathy Chaumerliac [France] ; Karine Desboeuf [France] ; Mimosa Manika [France] ; Haleh Bagheri [France] ; Olivier Rascol [France] ; Maryse Lapeyre-Mestre [France]Adverse drug reactions to selegiline : A review of the French Pharmacovigilance Database

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024